Vivus announced published data from its Phase 3 study of Qnexa (phentermine and topiramate) for the treatment of obesity and associated comorbidities including cardiovascular, metabolic and inflammatory risk factors. The CONQUER study included 2,487 overweight and obese patients with an average baseline BMI of 36.6kg/m2. It was a randomized, double-blind, placebo-controlled, three-arm prospective trial with patients randomized to receive once-daily treatment with mid or top dose Qnexa or placebo. Patients had a 4-week dose titration period followed by 52 weeks of treatment. Results showed that patients demonstrated statistically significant weight loss, reductions in blood pressure, improvement in lipid panel, and reduction in fasting insulin.

Qnexa is an oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increase satiety, the two main mechanisms that impact eating behavior. It is being developed to address weight loss, type 2 diabetes and obstructive sleep apnea.

For more information call (650) 934-5200 or visit www.vivus.com.